Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study - Report - MDSpire

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study

  • By

  • Lucía Pérez-Lamas

  • Adrián Segura Diaz

  • Regina García Delgado

  • Alberto Álvarez-Larrán

  • María Alicia Senin

  • Elvira Mora

  • María Laura Fox

  • Irene Pastor Galan

  • Gemma Azaceta

  • Sara Garrido Paniagua

  • Raúl Pérez Lopez

  • Diana Margarita Trejos Carvajal

  • Anna Angona

  • Carmen Albo López

  • Pablo Lorente Alegre

  • Miriam Vara

  • Juan Antonio Vera Goñi

  • Dunia De Miguel Llorente

  • Ángeles Fernández Rodríguez

  • Alberto Marín Sanchez

  • Adriana Hernando Megido

  • María Teresa Gómez Casares

  • Ruth Stuckey

  • Gonzalo Carreño-Tarragona

  • Natalia De Las Heras Rodriguez

  • Blanca Xicoy

  • Manuel Pérez Encinas

  • Raquel Mata Serna

  • Lucia Núñez Martin-Buitrago

  • Francisca Ferrer Marín

  • Neus Amer Salas

  • Carolina Guillén Rienda

  • Patricia Velez

  • Laura Lamarca Eraso

  • Sandra Martín

  • Iryna Luts Khoroz

  • Erik De Cabo López

  • Angela Gil

  • Sofía Martín-Consuegra Ramos

  • Fernando Marco De Lucas

  • María José́ Otero Martinez-Fornes

  • María Luisa Martín Mateos

  • Teresa Arquero

  • Elena Cabezudo Pérez

  • Luis Antonio López Gómez

  • Ángela Martínez Hellin

  • Aurelia Tejedor

  • Esther Herrera de Pablo

  • María Isabel Mata Vazquez

  • Inmaculada Castillo Valero

  • María José Fernández

  • Carlos Aguilar

  • Marta Santaliestra

  • Antonio García Menchon

  • Begoña Navas Elorza

  • María Antonia Duran

  • María Pérez Sala

  • Teresa Hernández Santamaría

  • Ma Ángeles Muñoz Jarreño

  • Julio Dávila-Valls

  • Williana Torres Jiménez

  • Joan Alfons Gonzálvez Fernández

  • Hugo Alexander Torres Mantilla

  • Teresa Cobo Rodríguez

  • Aitor Abuin Blanco

  • Francisco Pérez

  • Santiago Osorio Prendes

  • Paola Beneit Villena

  • Raisa Peralta

  • Federico Herrera

  • Eloi Cañamero Giro

  • Reyes Jiménez Bárcenas

  • Mercedes Gasior Kabat

  • Sonia González De Villambrosia

  • Mariana Teresa Tercero-Mora Rodriguez

  • Marina Menéndez Cuevas

  • Beatriz Cuevas Ruiz

  • Marta Fonseca-Santos

  • Sonia Garcés Piquer

  • Rosalía De La Puerta

  • Álvaro Lorenzo Vizcaya

  • Juan Carlos Hernández Boluda

  • Valentín García Gutiérrez

  • April 17, 2025

  • 0 min

Share

Outcomes in Myelofibrosis Patients with Anemia Treated with Momelotinib: MOMGEMFIN Trial

Overview

The MOMGEMFIN study evaluated momelotinib in 154 myelofibrosis patients with anemia, demonstrating significant anemia improvement, reduced transfusion dependency, and spleen size reduction. Both JAK inhibitor–naïve and exposed patients showed clinical benefit, with combination therapy potentially accelerating anemia response.

Background

Myelofibrosis (MF) is commonly treated with JAK inhibitors like ruxolitinib and fedratinib, but their efficacy is limited by transient responses and cytopenias. Momelotinib, recently approved by FDA and EMA, inhibits JAK1/JAK2 and ACVR1, impacting iron metabolism and anemia. Clinical trials have shown momelotinib improves symptoms, spleen size, hemoglobin levels, and reduces transfusion needs. The MOMGEMFIN study provides real-world evidence on momelotinib’s effectiveness and safety in MF patients with anemia.

Data Highlights

ParameterValue
Number of patients154
Median age73 years (42–87)
Prior JAKi exposure118 (76.6%)
Median Hb at baseline (anemia cohort)8.0 g/dL (4.7–10.8)
Transfusion dependency in anemia cohort73.8%
Median RBC transfusions/month in TDA group (baseline)4 units (1–8)
Major anemia response at 3 months (TDA)26.9%
Minor anemia response at 3 months (TDA)31.3%
Median Hb increase at 3 months (TDA)7.7 to 8.7 g/dL
Transfusion independence at 3 months (TDA)48.4%
Spleen size reduction in evaluable patients62.2% with median 5 cm decrease
Spleen response rate (2013 ELN criteria)24.4%

Key Findings

  • Among transfusion-dependent anemia (TDA) patients, 26.9% achieved major anemia response and 31.3% minor response at 3 months, with median hemoglobin rising from 7.7 to 8.7 g/dL.
  • Transfusion frequency in TDA patients decreased from 4 units/month at baseline to 1 unit/month at 3 and 6 months, with nearly half achieving transfusion independence at 3 months.
  • Non-TDA patients showed major anemia response rates of 47.8% at 3 months and median hemoglobin increase from 8.9 to 10.2 g/dL.
  • Combination therapy of momelotinib with erythropoietin-stimulating agents (ESAs) led to higher early anemia response rates (71.5% vs. 50% at 3 months) compared to momelotinib monotherapy.
  • 62.2% of patients with baseline splenomegaly >5 cm experienced spleen size reduction, with a median decrease of 5 cm; 24.4% met spleen response criteria.
  • Both JAK inhibitor–exposed and naïve patients benefited, though JAKi-exposed patients had higher anemia response rates in the non-TDA group, possibly due to prior toxicity.

Clinical Implications

Momelotinib is effective in improving anemia and reducing transfusion requirements in MF patients, including those previously treated with JAK inhibitors. Early combination with ESAs may enhance anemia response, suggesting a potential strategy for managing symptomatic anemia. Additionally, momelotinib provides meaningful spleen size reduction, supporting its role as a comprehensive treatment option in MF with anemia.

Conclusion

The MOMGEMFIN trial confirms momelotinib’s efficacy in improving anemia, decreasing transfusion dependency, and reducing splenomegaly in myelofibrosis patients with anemia, including those with prior JAK inhibitor exposure. These findings support momelotinib as a valuable therapeutic option in routine clinical practice.

References

  1. GEMFIN MOMGEMFIN Study 2024 -- Outcomes in Myelofibrosis Patients with Anemia Treated with Momelotinib

Original Source(s)

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study

  • by Lucía Pérez-Lamas, Adrián Segura Diaz, Regina García Delgado, Alberto Álvarez-Larrán, María Alicia Senin, Elvira Mora, María Laura Fox, Irene Pastor Galan, Gemma Azaceta, Sara Garrido Paniagua, Raúl Pérez Lopez, Diana Margarita Trejos Carvajal, Anna Angona, Carmen Albo López, Pablo Lorente Alegre, Miriam Vara, Juan Antonio Vera Goñi, Dunia De Miguel Llorente, Ángeles Fernández Rodríguez, Alberto Marín Sanchez, Adriana Hernando Megido, María Teresa Gómez Casares, Ruth Stuckey, Gonzalo Carreño-Tarragona, Natalia De Las Heras Rodriguez, Blanca Xicoy, Manuel Pérez Encinas, Raquel Mata Serna, Lucia Núñez Martin-Buitrago, Francisca Ferrer Marín, Neus Amer Salas, Carolina Guillén Rienda, Patricia Velez, Laura Lamarca Eraso, Sandra Martín, Iryna Luts Khoroz, Erik De Cabo López, Angela Gil, Sofía Martín-Consuegra Ramos, Fernando Marco De Lucas, María José́ Otero Martinez-Fornes, María Luisa Martín Mateos, Teresa Arquero, Elena Cabezudo Pérez, Luis Antonio López Gómez, Ángela Martínez Hellin, Aurelia Tejedor, Esther Herrera de Pablo, María Isabel Mata Vazquez, Inmaculada Castillo Valero, María José Fernández, Carlos Aguilar, Marta Santaliestra, Antonio García Menchon, Begoña Navas Elorza, María Antonia Duran, María Pérez Sala, Teresa Hernández Santamaría, Ma Ángeles Muñoz Jarreño, Julio Dávila-Valls, Williana Torres Jiménez, Joan Alfons Gonzálvez Fernández, Hugo Alexander Torres Mantilla, Teresa Cobo Rodríguez, Aitor Abuin Blanco, Francisco Pérez, Santiago Osorio Prendes, Paola Beneit Villena, Raisa Peralta, Federico Herrera, Eloi Cañamero Giro, Reyes Jiménez Bárcenas, Mercedes Gasior Kabat, Sonia González De Villambrosia, Mariana Teresa Tercero-Mora Rodriguez, Marina Menéndez Cuevas, Beatriz Cuevas Ruiz, Marta Fonseca-Santos, Sonia Garcés Piquer, Rosalía De La Puerta, Álvaro Lorenzo Vizcaya, Juan Carlos Hernández Boluda, Valentín García Gutiérrez

  • April 17, 2025

Related Content

Triple-negative primary myelofibrosis: a comparative analysis of phenotype, genotype, and outcome

Impact of Neutropenia on the Effectiveness of Artemisinin-Based Combination Therapy in Pregnant Women in Mali

Rare Case report and Literature Review of Peripheral T-Cell Lymphoma Presenting as Massive Gastrointestinal Hemorrhage: An Unusual Etiology Demanding Emergency Surgical Intervention